Scarica l'app Stockscreener
114.22
3.11%
3.45
Dopo l'orario di chiusura:
114.22
Celcuity Inc Borsa (CELC) Ultime notizie
Celcuity prices $248.7M debt, stock offerings - MSN
The Bull Case For Celcuity (CELC) Could Change Following Strong VIKTORIA-1 Gedatolisib Phase 3 Data - simplywall.st
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference - Yahoo Finance
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - AOL.com
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug - The Motley Fool
Wolfe Research Maintains Outperform on Celcuity Inc (CELC) Mar 12, 2026 - Meyka
Celcuity’s Gedatolisib Advances With Pivotal Data And FDA Priority Review - simplywall.st
Celcuity publishes Phase 3 trial results in medical journal By Investing.com - Investing.com Nigeria
Celcuity stock maintained at Outperform by Wolfe on efficacy outlook - Investing.com
Celcuity Stock Pre-Market (-0.2%): Needham Raises Target on Strong Data Publication - Trefis
Buyback Watch: Can Celcuity Inc ride the EV waveEarnings Risk Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount? - simplywall.st
Assessing Celcuity (CELC) Valuation After Strong Recent Returns And Optimistic Growth Forecasts - Sahm
CELC: Gedatolisib delivers record efficacy in breast cancer, with launch and global expansion plans advancing - TradingView
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing - Yahoo Finance
Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results - MSN
Needham Raises Price Target for Celcuity (CELC) to $122 | CELC S - GuruFocus
Celcuity (NASDAQ:CELC) Price Target Raised to $122.00 - MarketBeat
Needham raises Celcuity stock price target on priority review status By Investing.com - Investing.com Nigeria
Needham raises Celcuity stock price target on priority review status - Investing.com
Celcuity publishes Phase 3 trial results in medical journal - Investing.com South Africa
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology - Bitget
Celcuity Announces Publication of Results from PIK3CA - GlobeNewswire
Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference - MarketBeat
Buybacks Report: Should I set a stop loss on Celcuity IncDollar Strength & Breakout Confirmation Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (CELC) - Stock Traders Daily
Vanguard Group Inc. Raises Stock Position in Celcuity, Inc. $CELC - MarketBeat
CELC Stock Price, Quote & Chart | CELCUITY INC (NASDAQ:CELC) - ChartMill
CELC: Gedatolisib nears launch with strong trial data, regulatory momentum, and $10B+ peak potential - TradingView
TD Asset Management Inc Invests $3.60 Million in Celcuity, Inc. $CELC - MarketBeat
Artisan Partners Limited Partnership Boosts Stock Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity Inc. (CELC) - DirectorsTalk Interviews
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
A Look At Celcuity (CELC) Valuation After Charles Romp Joins The Board And Gedatolisib Progress - simplywall.st
Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise - Yahoo Finance
Bull Run: Should I set a stop loss on Celcuity IncJuly 2025 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (CELC) Movement - Stock Traders Daily
Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy? - simplywall.st
Patient Square Capital LP Acquires Shares of 100,000 Celcuity, Inc. $CELC - MarketBeat
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - AOL.com
Soleus Adds a Significant Number of Celcuity Shares - AOL.com
Perceptive Advisors Increases Stake in Celcuity - Intellectia AI
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuit - GuruFocus
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuity Inc - GuruFocus
Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator’s 9.29% Upside Captures Investor Attention - DirectorsTalk Interviews
Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Decliners Report: How does Celcuity Inc correlate with Nasdaq2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):